Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy.

Imagen de Magaly Martinez-Ferrer
PDF versionPDF version
TítuloChemokine markers predict biochemical recurrence of prostate cancer following prostatectomy.
Publication TypeJournal Article
Year of Publication2008
AutoresBlum, DL, Koyama, T, M'Koma, AE, Iturregui, JM, Martinez-Ferrer, M, Uwamariya, C, Smith, JA, Clark, PE, Bhowmick, NA
JournalClin Cancer Res
Volume14
Issue23
Pagination7790-7
Date Published2008 Dec 1
ISSN1078-0432
Palabras claveAdenocarcinoma, Aged, Area Under Curve, Case-Control Studies, Chemokine CCL4, Chemokine CX3CL1, Humans, Interleukin-15, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Prostatectomy, Prostatic Neoplasms, ROC Curve, Sensitivity and Specificity, Tumor Markers, Biological
Abstract

PURPOSE: Stratifying patients who have a high risk of prostate cancer recurrence following prostatectomy can potentiate the use of adjuvant therapy at an early stage. Inflammation has emerged as a mediator of prostate cancer metastatic progression. We hypothesized that chemokines can be biomarkers for distinguishing patients with high risk for biochemical recurrence of prostate cancer.

EXPERIMENTAL DESIGN: In a nested case-control study, 82 subjects developed biochemical recurrence within 5 years of prostatectomy. Prostate tissues from 98 age-matched subjects who were recurrence-free following prostatectomy in the same period were the controls. A high-throughput lectin-based enrichment of prostate tissue enabled multiplex ELISA to identify the expression of three chemokines to discriminate the two patient populations.

RESULTS: The expression of CX3CL1 and IL-15 in prostate tissue was associated with 5-year biochemical recurrence-free survival following prostatectomy. However, the expression of chemokine ligand 4 (CCL4) was associated with biochemical recurrence. Multivariable logistic regression model combining preoperative prostate-specific antigen, Gleason score, surgical margin, and seminal vesicle status with the three chemokines doubled the specificity of prediction at 90% sensitivity compared with use of the clinicopathologic variables alone (P < 0.0001). Survival analysis yielded a nomogram that supported the use of CX3CL1, IL-15, and CCL4 in predicting 1-, 3-, and 5-year recurrence-free survival after prostatectomy.

CONCLUSIONS: Each of the three chemokines can serve as independent predictors of biochemical recurrence. However, the combination of chemokine biomarkers plus clinicopathologic variables discriminated prostatectomy subjects for the probability of biochemical recurrence significantly better than clinicopathologic variables alone.

DOI10.1158/1078-0432.CCR-08-1716
Alternate JournalClin. Cancer Res.
PubMed ID19047106
PubMed Central IDPMC3050736
Grant List5K12GM068543 / GM / NIGMS NIH HHS / United States
R01 CA108646 / CA / NCI NIH HHS / United States
R01 CA108646-04 / CA / NCI NIH HHS / United States